IGF2BP1 promotes multiple myeloma with chromosome 1q gain via increasing CDC5L expression in an m⁶A-dependent manner.

ABSTRACT: Multiple myeloma (MM) patients with chromosome 1q gain (1q+) are clinically and biologically heterogeneous. The underlying molecular mechanisms are still under investigation, while the identification of targets for effective therapy of this subgroup of MM patients is urgently needed. We aimed to investigate the clinical significance and the regulatory mechanisms of insulin-like growth factor 2 messenger RNA (mRNA) binding protein 1 (IGF2BP1), a N6-methyladenosine (m⁶A) reader, in MM patients with 1q+. We found that MM patients with 1q+ exhibit a significantly higher level of IGF2BP1 mRNA than controls, while higher IGF2BP1 expression predicted a worse prognosis in MM patients with 1q+. IGF2BP1 overexpression promoted cell proliferation and G1-to-S phase transition of the cell cy

SUBMITTER: Xu J 

PROVIDER: S-EPMC11554607 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature